Global and United States Primary Sclerosing Cholangitis Treatment Market Report & Forecast 2022-2028

Primary sclerosing cholangitis is a chronic liver disease that may occur alone or be caused by other diseases.The disease is characterized by inflammation and thickening of the bile ducts.This impedes bile flow and may lead to other liver diseases.Primary sclerosing cholangitis (PSC) is treated in addition to PSC and avoids other liver diseases.Available options are liver transplantation, UDCA drugs, and PSC drugs, each with advantages and disadvantages in cost and efficacy.
Market Analysis and Insights: Global and United States Primary Sclerosing Cholangitis Treatment Market
This report focuses on global and United States Primary Sclerosing Cholangitis Treatment market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Primary Sclerosing Cholangitis Treatment market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, Liver Transplantation Operation accounting for % of the Primary Sclerosing Cholangitis Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospital was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Primary Sclerosing Cholangitis Treatment market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Primary Sclerosing Cholangitis Treatment Scope and Market Size
Primary Sclerosing Cholangitis Treatment market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Primary Sclerosing Cholangitis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Primary Sclerosing Cholangitis Treatment market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Liver Transplantation Operation
UDCA Drugs
PSC Drugs
Segment by Application
Hospital
Clinics
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Allergan
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Dr. Falk Pharma
Daewoong Pharmaceutical
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Bruschettini
Shanghai Pharma
Grindeks
Acorda Therapeutics
Gilead Sciences
Intercept Pharmaceuticals
Shire Plc
NGM Biopharmaceuticals
Conatus Pharmaceuticals
Durect Corporation
Sirnaomics
Shenzhen HighTide Biopharmaceuticals